Dianthus Therapeutics, Inc.
DNTH
$16.86
-$0.585-3.35%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -114.66% | -169.24% | -70.52% | -58.05% | -93.93% |
| Total Depreciation and Amortization | 24.30% | -24.27% | 29.02% | -16.98% | 32.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 124.85% | 573.37% | 43.12% | 629.41% | 766.86% |
| Change in Net Operating Assets | 40.97% | 73.51% | -32.23% | -95.24% | 18.37% |
| Cash from Operations | -84.93% | -131.52% | -112.84% | -207.08% | -45.28% |
| Capital Expenditure | 25.00% | -210.00% | 61.54% | 19.05% | -128.57% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 370.65% | -180.53% | -2,166.95% | -94.58% | -130.17% |
| Cash from Investing | 368.64% | -180.56% | -2,154.36% | -94.65% | -130.37% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.93% | -- | 5,820.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -100.00% | -- | -- |
| Cash from Financing | -99.93% | 915.54% | -99.79% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.42% | 56.41% | -339.72% | -190.79% | 2,415.60% |